What is Kabra Drugs share price return in the past 10 years?

Kabra Drugs Ltd share price has declined -2.6% annually (CAGR) over the past ten years.

Kabra Drugs Ltd - Stock Valuation and Financial Performance

Name: Kabra Drugs
Brand: Kabra Drugs

BSE: 524322 | NSE: | Pharmaceuticals & Drugs | Small Cap

Place order

Kabra Drugs Share Price

₹7.19 0.00 0.00%
as on 22-Apr'24 16:01

DeciZen - make an informed investing decision on Kabra Drugs

Based on:

Data

M-Cap below 100cr DeciZen not available

Kabra Drugs stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

3.2 Cr.

52-wk low:

3.2

52-wk high:

7.2

Is Kabra Drugs Ltd an attractive stock to invest in?

1. Is Kabra Drugs Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Kabra Drugs Ltd is a below average quality company.

2. Is Kabra Drugs Ltd undervalued or overvalued?

The key valuation ratios of Kabra Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Kabra Drugs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Kabra Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Kabra Drugs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	2.6%	2.4%	3.9%	6.1%	-57.8%	-19.9%	-8.9%	-27.3%	-27.8%	-52.6%	-
Value Creation Index ⓘ	-0.8	-0.8	-0.7	-0.6	-5.1	-2.4	NA	NA	NA	NA	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	11.4	8.3	9.7	7.6	2	0	0	0	0	0	0
Sales YoY Gr.	-	-27.7%	16.8%	-21.1%	-73.6%	-100%	NA	NA	NA	NA	-
Adj EPS ⓘ	0.2	0.2	0.1	0.3	-3.9	-0.4	-0.1	-0.4	-0.4	-0.8	-1.2
YoY Gr.	-	-33.3%	-62.5%	400%	-1386.7%	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	6.7	5.9	6	5.8	0.5	0.1	-0.1	-0.5	-0.9	-1.7	-2.5
Adj Net Profit ⓘ	0.1	0.1	0	0.1	-1.7	-0.2	-0.1	-0.2	-0.2	-0.3	-1
Cash Flow from Ops. ⓘ	0	-0.2	0.3	0.3	-0.1	-0.2	-0.1	-0.3	-0.1	-0.4	-
Debt/CF from Ops. ⓘ	-40926.6	-6.3	4.5	5.8	-6.1	-3.8	-14.2	-3.6	-7.7	-3.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-100%	-100%	NA	NA
Adj EPS ⓘ	-213.8%	NA	NA	NA
BVPSⓘ	-185.7%	-230%	NA	NA
Share Price	-2.6%	65.5%	20.7%	33.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	3.6	2.6	1.1	5	-123.2	-144.2	-2869.3	152.9	61.4	60.1	55.6
Op. Profit Mgn % ⓘ	5	4.8	4.7	5.8	-51.5	0	0	0	0	0	NAN
Net Profit Mgn % ⓘ	0.9	0.9	0.3	1.7	-84.4	0	0	0	0	0	-INF
Debt to Equity ⓘ	1	0.5	0.5	0.7	3.6	21	-23.5	-4.3	-2.6	-1.9	-
Working Cap Days ⓘ	168	240	213	229	460	0	0	0	0	0	0
Cash Conv. Cycle ⓘ	90	130	102	91	310	0	0	0	0	0	0

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 55.60%

Sales growth has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Kabra Drugs Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-1.2	-
TTM Sales (₹ Cr.)	0	-
BVPS (₹.) ⓘ	-2.5	-
Reserves (₹ Cr.) ⓘ	-5	-
P/BV ⓘ	-2.88	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	3.18 / 7.19
All Time Low / High (₹)	0.52 / 160.70
Market Cap (₹ Cr.)	3.2
Equity (₹ Cr.)	4.4
Face Value (₹)	10
Industry PE ⓘ	47.9

Management X-Ray of Kabra Drugs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Kabra Drugs

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Kabra Drugs

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	11.42	8.26	9.65	7.61	2.01	0	0	0	0	0
Operating Expenses ⓘ	10.88	7.86	9.20	7.17	3.04	0.14	0.05	0.15	0.18	0.34
Manufacturing Costs	1.56	0.95	1.33	0.94	0.22	0	0	0	0	0
Material Costs	7.81	5.29	6.52	4.14	1.38	0	0	0	0	0
Employee Cost	0.66	0.64	0.68	0.83	1.18	0.03	0	0.05	0.09	0.23
Other Costs ⓘ	0.85	0.98	0.67	1.25	0.26	0.10	0.05	0.10	0.09	0.11
Operating Profit ⓘ	0.54	0.40	0.46	0.44	-1.03	-0.14	-0.05	-0.15	-0.18	-0.34
Operating Profit Margin (%)	4.7%	4.8%	4.7%	5.8%	-51.5%	-	-	-	-	-
Other Income ⓘ	0	0.01	0.02	0.11	0.01	0.01	0.02	0	0	0.01
Interest ⓘ	0.07	0.07	0.18	0.17	0.25	0.01	0	0	0	0
Depreciation ⓘ	0.26	0.23	0.24	0.24	0.14	0.03	0.03	0.03	0.01	0
Exceptional Items ⓘ	0	0	0	0	-0.95	0	0	0	0	0
Profit Before Tax ⓘ	0.21	0.11	0.05	0.14	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34
Tax ⓘ	0.13	0.04	0.02	0.01	0	0	0	0	0	0
Profit After Tax	0.09	0.07	0.03	0.13	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34
PAT Margin (%)	0.8%	0.9%	0.3%	1.7%	-117.0%	-	-	-	-	-
Adjusted EPS (₹)	0.2	0.2	0.1	0.3	-5.4	-0.4	-0.1	-0.4	-0.4	-0.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	2.93	2.60	2.63	2.55	0.20	0.03	-0.03	-0.21	-0.39	-0.73
Share Capital ⓘ	4.39	4.39	4.39	4.39	4.39	4.39	4.39	4.39	4.39	4.39
Reserves ⓘ	-1.46	-1.78	-1.76	-1.84	-4.19	-4.36	-4.42	-4.60	-4.78	-5.12
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	3.01	1.37	1.28	1.68	0.66	0.67	0.65	0.90	1.03	1.38
Long Term Debt	2.28	1.23	1.18	1.03	0.01	0.02	0	0	0	0
Short Term Debt	0.73	0.15	0.10	0.65	0.65	0.65	0.65	0.90	1.03	1.38
Trade Payables	1.90	2.08	2.79	1.28	0.21	0.19	0.19	0.19	0	0
Others Liabilities ⓘ	1.37	2.48	2.47	0.88	0.63	0.59	0.60	0.52	0.10	0.05
Total Liabilities ⓘ	9.21	8.54	9.17	6.39	1.70	1.48	1.41	1.40	0.73	0.70
Fixed Assets
Gross Block	8.72	8.83	9.02	2.73	0.17	0.17	0.17	0.17	0.17	0.17
Accumulated Depreciation	5.42	6.04	6.29	0.24	0.06	0.09	0.13	0.16	0.17	0.17
Net Fixed Assetsⓘ	3.30	2.78	2.73	2.48	0.11	0.08	0.04	0.01	0	0
CWIP ⓘ	0	0.10	0.21	0.21	0	0	0	0	0	0
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0.76	0.41	0.32	0.22	0	0	0	0	0	0
Trade Receivables	4.58	4.47	5.36	2.95	1.26	1.25	1.25	1.25	0.60	0.60
Cash Equivalents	0.28	0.44	0.16	0.09	0.13	0.01	0.01	0.01	0	0
Others Assetsⓘ	0.28	0.34	0.39	0.43	0.20	0.14	0.11	0.13	0.13	0.10
Total Assets ⓘ	9.21	8.54	9.17	6.39	1.70	1.48	1.41	1.40	0.73	0.70

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	0	-0.22	0.28	0.31	-0.12	-0.18	-0.05	-0.25	-0.13	-0.35
PBT ⓘ	0.21	0.11	0.05	0.14	-2.36	-0.16	-0.06	-0.18	-0.19	-0.34
Adjustment ⓘ	-0.21	0.29	0.41	0.30	1.32	0.03	0.01	0.03	0.01	0
Changes in Working Capital ⓘ	0.13	-0.58	-0.15	-0.12	0.94	-0.04	0	-0.1	0.04	-0.02
Tax Paid ⓘ	-0.13	-0.04	-0.02	-0.01	-0.02	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-0.14	-0.20	-0.29	0.01	1.50	0.07	0.06	0	0	0
Capex	-0.15	-0.21	-0.31	0	1.50	0	0.01	0	0	0
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0.01	0.02	0.01	0	0.07	0.06	0	0	0
Cash Flow From Financing Activityⓘ	0.14	0.58	-0.27	-0.32	-1.35	0	-0.02	0.25	0.13	0.36
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	-1.10	0.01	-0.02	0	0	0
Interest Paid ⓘ	-0.06	-0.07	-0.18	-0.17	-0.25	-0.01	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.20	0.64	-0.09	-0.15	0	0	0	0.25	0.13	0.36
Net Cash Flow ⓘ	0	0.16	-0.28	0	0.04	-0.10	0	0	-0.01	0

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	2.99	2.55	1.05	5.02	-171.4	-144.2	N/A	N/A	N/A	N/A
ROCE (%)	4.82	3.52	5.81	7.49	-80.09	-19.67	N/A	N/A	N/A	N/A
Asset Turnover Ratio	1.28	0.93	1.09	0.99	0.5	0	0	0	0	0
PAT to CFO Conversion(x)	0	-3.14	9.33	2.38	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	135	200	186	197	383	0	0	0	0	0
Inventory Days	21	26	14	13	0	0	0	0	0	0
Payable Days	92	137	136	179	196	0	0	0	0	0

Kabra Drugs Ltd Stock News

Kabra Drugs Ltd FAQs

What is the share price of Kabra Drugs?

Company share prices are keep on changing according to the market conditions. The closing price of Kabra Drugs on 22-Apr-2024 16:01 is ₹7.19.

What is the market cap of Kabra Drugs?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Apr-2024 16:01 the market cap of Kabra Drugs stood at ₹3.16.

What is the P/E ratio of Kabra Drugs?

The latest P/E ratio of Kabra Drugs as of 22-Apr-2024 16:01 is 0.00.

What is the P/B ratio of Kabra Drugs?

The latest P/B ratio of Kabra Drugs as of 22-Apr-2024 16:01 is -2.88.

What is the 52-week high and low of Kabra Drugs?

The 52-week high of Kabra Drugs is ₹7.19 and the 52-week low is ₹3.18.

What is the TTM revenue of Kabra Drugs?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kabra Drugs is ₹0.00 ( Cr.) .

About Kabra Drugs Ltd

Kabra Drugs Ltd. is a limited company incorporated under the Companies Act, 1956 on August 22, 1989 having its registered office at 270 Shastri Market Indore, MP. The company is a public limited Company and its shares are listed on Bombay stock exchange (BSE).

Business area of the company

The company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products.